Based on the Selexis SUREtechnology Platform™ and world-class expertise, Selexis SURE Cell line development™ Services significantly reduces the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g. monoclonal antibodies, growth factors, enzymes).
The development of high-yield production cell lines begins with the cloning of target genes into the SUREtech Vectors™ containing Selexis Genetic Elements™ (SGEs). These target gene-containing vectors are transfected either into the Selexis SURE CHO-M Cell line™ or another fully documented cell line provided by the client using the SUREfection™ procedure. From the stable transfectant population, and using up to two limiting dilution steps, Selexis selects for high expressing populations with favorable growth characteristics. A secondary limiting dilution step (single cell dilution) can be carried out, if necessary, to generate more clonal populations with even higher protein expression levels, SUREclones™.
